Breast cancer: Tamoxifen benefits node-positive elders after mastectomy

August 1991
Geriatrics;Aug1991, Vol. 46 Issue 8, p17
Academic Journal
This article presents a study, conducted by Frank Cummings and colleagues, who analyzed findings in 168 older women with node-positive breast cancer who were treated for 2 years following mastectomy with either tamoxifen, 20 mg/d, or placebo. Of 102 deaths in this series, 61% were due to breast cancer; 22% of deaths followed other illness without recurrence of breast cancer. Overall, the data support, the use of tamoxifen as the treatment choice in elderly women with node-positive breast cancer after a mastectomy.


Related Articles

  • Fulvestrant: A Viewpoint by Roger W. Blamey. Blamey, R.W. // Drugs;Apr2001, Vol. 61 Issue 6, p814 

    Presents information on fulvestrant, an anti-estrogen antagonist, indicated for treating breast cancer. Comparison between fulvestrant and tamoxifen as estrogen receptors; Limitations of the effect of the fulvestrant.

  • Tamoxifen: In whose best interest? Oakley, Ann // New Scientist;6/22/91, Vol. 130 Issue 1774, p12 

    Discusses the issues involved in the trials of tamoxifen for the treatment of breast cancer. Study by Trevor Powles of the Royal Marsden Hospital in England; Statistics of breast cancer in the UK; Need for women in the study to be given clear and complete information about the drug; History of...

  • Aromatase inhibitor cuts risk of recurrence of breast cancer. White, Caroline // BMJ: British Medical Journal (International Edition);3/13/2004, Vol. 328 Issue 7440, p599 

    Reports on the treatment of postmenopausal women with breast cancer. Evaluation of the switch to the aromatase inhibitor exemestane after treatment with tamoxifen; Reference to a study found in a 2004 issue of the "New England Journal of Medicine"; Report that women treated with exemestane were...

  • Lumpectomy plus Tamoxifen with or without Irradiation in Women 70 Years of Age or Older with Early Breast Cancer. Hughes, Kevin S.; Schnaper, Lauren A.; Berry, Donald; Cirrincione, Constance; McCormick, Beryl; Shank, Brenda; Wheeler, Judith; Champion, Lorraine A.; Smith, Thomas J.; Smith, Barbara L.; Shapiro, Charles; Muss, Hyman B.; Winer, Eric; Hudis, Clifford; Wood, William; Sugarbaker, David; Henderson, I. Craig; Norton, Larry // New England Journal of Medicine;9/2/2004, Vol. 351 Issue 10, p971 

    Background: In women 70 years of age or older who have early breast cancer, it is unclear whether lumpectomy plus tamoxifen is as effective as lumpectomy followed by tamoxifen plus radiation therapy. Methods: Between July 1994 and February 1999, we randomly assigned 636 women who were 70 years...

  • Breast Cancer Patients Switched to Pfizer's Aromasin Were More Likely to Remain Cancer Free, Study Shows; Results From Pfizer-Sponsored Study Challenge Standard Tamoxifen Therapy.  // Ascribe Newswire: Medicine;3/22/2004, p22 

    Post-menopausal breast cancer patients who switched from tamoxifen to Aromasin had a significantly reduced chance of recurrence and increased disease-free survival compared to patients who remained on tamoxifen, according to new data published in the March 22, 2004 issue of the "New England...

  • Breast cancer risk can be cut by 32%. Moberly, Tom // GP: General Practitioner;8/5/2011, p10 

    The article offers information on the treatment with tamoxifen, which reduces the risk factors of breast cancer among women by 32 percent. It states that according to a research taking tamoxifen for the full five-year treatment period reduces women's chances of dying from hormone-sensitive...

  • Study Shows New Breast Cancer Drug Letrozole Shrinks Tumors More Effectively Than Tamoxifen.  // Ascribe Newswire: Medicine;12/10/2001, p18 

    A new cancer drug called letrozole (trade name Femara) worked better at shrinking breast cancer tumors than did the front-line breast cancer drug tamoxifen among a group of postmenopausal women with estrogen-positive tumors, according to a study coordinated by a Duke University Medical Center...

  • POEM. Coombes, R.C.; Hall, E.; Gibson, L.J. // BMJ: British Medical Journal (International Edition);7/10/2004, Vol. 329 Issue 7457, p0 

    Presents a summary of a study on the use of exemestane in the years 2-5 after breast cancer. Question; Synopsis; Bottom line that exemestane does improve outcomes for postmenopausal women with oestrogen receptor positive breast cancer after 2-3 years of treatment with tamoxifen; Level of evidence.

  • Breast Cancer.  // Encyclopedic Reference of Molecular Pharmacology;2004, p198 

    The article presents an encyclopedia entry for breast cancer. It is a cancer of the breast tissue and major part of it in women is dependent on the female sex hormones for their growth. To limit the growth of the tumor and to treat the cancer, an estrogen antagonist can be used. It can also be...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics